Ortho RTI shared additional chemistry, manufacturing and control information to the FDA, according to a July 20 news release.
The data is a response to a clinical hold letter the FDA sent Ortho RTI in June regarding Ortho-R, a biologic drug. Ortho-R received classification as a biologic drug last year.
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
